How big is the Canada Insulin Drugs And Delivery Devices Market?

The Canada Insulin Drugs And Delivery Devices Market size is expected to reach USD 1.68 billion in 2024 and grow at a CAGR of 1.7% to reach USD 1.83 billion by 2029. Read More

What is the current Canada Insulin Drugs And Delivery Devices Market size?

In 2024, the Canada Insulin Drugs And Delivery Devices Market size is expected to reach USD 1.68 billion. Read More

Who are the key players in Canada Insulin Drugs And Delivery Devices Market?

Roche, NovoNordisk, Sanofi, Medtronics and Eli Lilly are the major companies operating in the Canada Insulin Drugs And Delivery Devices Market. Read More

What years does this Canada Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2023?

In 2023, the Canada Insulin Drugs And Delivery Devices Market size was estimated at USD 1.65 billion. The report covers the Canada Insulin Drugs And Delivery Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Canada Insulin Drugs And Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Canada Insulin Drugs And Delivery Devices Market

Canada Insulin Drugs And Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Canada Insulin Drugs and Delivery Devices Market is Segmented Into Drugs (Basal or Long-Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, Combination Insulins, And Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, And Jet Injectors). The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

Canada Insulin Drugs And Delivery Devices Industry Overview

The Canada Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.